Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Adverse Drug Event Reporting - NAPLEX

  1. A 79-year-old male (70 kg) is discharged from the hospital and brings new prescriptions to the pharmacy. He was prescribed digoxin 0.25 mg by mouth daily, but his prior home dose was digoxin 0.125 mg by mouth daily. Two days after starting the higher dose, he reports nausea, decreased appetite, and seeing "yellow halos." Current medications: furosemide 40 mg by mouth daily, carvedilol 12.5 mg by mouth twice daily, potassium chloride 20 mEq by mouth daily. Allergies: none known. Medical history: heart failure with reduced ejection fraction, atrial fibrillation, chronic kidney disease. Labs today: serum creatinine 2.0 mg/dL (baseline 1.8 mg/dL), potassium 3.2 mEq/L (low), digoxin concentration 2.6 ng/mL (high; typical goal 0.5–0.9 ng/mL in heart failure). Which action should the pharmacist take to address this adverse event?
    Answer: Advise the patient to stop digoxin and seek prompt medical evaluation; contact the prescriber about the dosing error and document the medication error per pharmacy policy This question tests recognition of digoxin toxicity and medication error management. The patient presents with classic digoxin toxicity symptoms (nausea, anorexia, yellow vision) after an apparent dosing error during hospital discharge, confirmed by elevated digoxin level (2.6 ng/mL) and predisposing factors (elderly, CKD, hypokalemia). Option B is correct because immediate discontinuation and medical evaluation are essential, the prescriber must be contacted about the dosing error, and the medication error requires documentation per pharmacy policy for quality improvement. Option A is dangerous as it continues toxic digoxin dosing and worsens hypokalemia. Option C is incorrect because digoxin is not a controlled substance requiring DEA reporting. Option D dangerously dismisses serious toxicity symptoms. The clinical pearl is that digoxin has a narrow therapeutic index with increased toxicity risk in elderly patients, renal impairment, and hypokalemia; medication reconciliation at transitions of care is critical to prevent dosing errors, and all medication errors should be documented for system improvement.
  2. A 56-year-old woman (74 kg) with hypothyroidism switched from one manufacturer of levothyroxine 100 mcg by mouth daily to another due to a formulary change 6 weeks ago. She now reports palpitations, anxiety, and weight loss. Current medications: levothyroxine 100 mcg daily (new manufacturer), calcium carbonate 500 mg twice daily. Medical history: hypothyroidism. Allergies: none. Labs: thyroid-stimulating hormone (TSH) 0.05 mIU/L (low; reference 0.4–4.0), free T4 elevated. Which monitoring parameter is critical for this patient on levothyroxine after a product change?
    Answer: Thyroid-stimulating hormone (TSH) recheck about 6 weeks after the change and after any dose/product adjustments This question assesses the monitoring of thyroid function following a levothyroxine product switch, which can lead to variations in bioavailability and potential over- or under-replacement. The key patient-specific factors include symptoms of hyperthyroidism such as palpitations, anxiety, and weight loss, corroborated by low TSH and elevated free T4 after switching manufacturers six weeks ago. Monitoring TSH about six weeks after the change and any subsequent dose or product adjustments is critical because levothyroxine has a long half-life, requiring this timeframe for steady-state assessment to ensure euthyroid status. Checking INR every three days is incorrect as the patient is not on warfarin, and while levothyroxine can enhance warfarin's effect indirectly through increased metabolism, no such interaction is relevant here. Monitoring serum potassium weekly for hyperkalemia or serum amylase monthly for pancreatitis is suboptimal as these are not associated with levothyroxine adjustments or the patient's presentation. A transferable clinical pearl is that brand switches in levothyroxine can cause up to 10-15% variability in absorption, necessitating TSH monitoring at 4-8 weeks post-change. In adverse event management for thyroid therapy, pharmacists should emphasize patient education on symptoms of imbalance and the importance of consistent product use to optimize outcomes.
  3. A 58-year-old man (90 kg) with chronic pain is found to have been dispensed oxycodone immediate-release 30 mg tablets instead of 5 mg tablets due to a selection error; he took 1 tablet every 6 hours for 2 days and now reports excessive sedation and pinpoint pupils. Current medications: oxycodone IR (incorrect strength), gabapentin 300 mg three times daily, lisinopril 20 mg daily. Medical history: obstructive sleep apnea. Allergies: none. Vitals in pharmacy: respiratory rate 10/min, oxygen saturation 90% on room air. Which action should the pharmacist take to address this adverse event?
    Answer: Call emergency services immediately for suspected opioid overdose, initiate naloxone if available per protocol, and notify the prescriber and pharmacy management per medication error policy This question tests the response to a medication dispensing error involving opioid overdose symptoms as an adverse event. The key patient-specific factor is the erroneous dispensing of oxycodone 30 mg instead of 5 mg, leading to excessive sedation, pinpoint pupils, and low respiratory rate after two days of use. Calling emergency services for suspected opioid overdose, initiating naloxone if available, and notifying the prescriber and pharmacy management per error policy is the best choice because it addresses life-threatening respiratory depression promptly and ensures error documentation for quality improvement. Advising to skip the next dose is incorrect as it does not address current overdose symptoms, while reporting only to MedWatch delays urgent care. Recommending diphenhydramine is suboptimal as it could worsen sedation without reversing opioid effects. A transferable pearl is to recognize opioid toxicity triad (sedation, miosis, respiratory depression) and prioritize reversal with naloxone. In adverse event reporting, follow ISMP guidelines for medication errors, including root cause analysis and voluntary submission to FDA or state boards.
  4. A 66-year-old man (84 kg) with atrial fibrillation is on warfarin and presents for follow-up after starting amiodarone 200 mg by mouth daily 1 week ago. Current medications: warfarin 5 mg daily, amiodarone 200 mg daily (new), simvastatin 20 mg nightly. Medical history: atrial fibrillation, hyperlipidemia. Allergies: none. Labs: INR 4.8 (goal 2–3), AST/ALT within normal limits. What is the best recommendation for preventing future adverse events in this patient?
    Answer: Implement closer INR monitoring and coordinate a warfarin dose reduction due to the interaction with amiodarone This question tests the prevention of adverse events from the drug-drug interaction between warfarin and amiodarone. The key patient-specific factor is the elevated INR of 4.8 one week after starting amiodarone in a patient on stable warfarin. Implementing closer INR monitoring and coordinating a warfarin dose reduction is the best recommendation because amiodarone inhibits warfarin metabolism via CYP2C9, potentiating anticoagulation and bleeding risk. Increasing warfarin is incorrect as amiodarone increases, not decreases, its effect, while stopping INR monitoring is dangerous. Switching simvastatin to atorvastatin does not address the INR elevation. A transferable pearl is to anticipate a 30-50% warfarin dose reduction with amiodarone and monitor INR weekly initially. In adverse event prevention, use interaction checkers and a framework like adjusting doses based on interaction severity and patient factors.
  5. A 64-year-old man (92 kg) on chronic prednisone 10 mg daily is prescribed levofloxacin 750 mg by mouth daily for pneumonia. Three days later he reports sudden heel pain and difficulty walking. Current medications: prednisone 10 mg daily, levofloxacin 750 mg daily (new), albuterol inhaler as needed. Medical history: COPD. Allergies: none. Labs: SCr 1.0 mg/dL. Which symptom reported by the patient is most indicative of an adverse drug reaction?
    Answer: Sudden heel pain and difficulty walking after starting levofloxacin This question tests the identification of tendon-related adverse effects from fluoroquinolones, particularly in patients on corticosteroids. The key patient-specific factor is the sudden heel pain and difficulty walking 3 days after starting levofloxacin in a patient on chronic prednisone. Sudden heel pain and difficulty walking is most indicative of an adverse drug reaction because fluoroquinolones increase tendon rupture risk, amplified by corticosteroids. Mild nausea is less specific and common with many antibiotics, while increased appetite is expected with prednisone. Occasional dry mouth is suboptimal as it is non-specific and self-resolving. A clinical pearl is to avoid fluoroquinolones in patients over 60 or on steroids unless no alternatives, and counsel on stopping at first tendon pain sign. For adverse event reporting, document in the patient profile and submit to MedWatch if rupture occurs, emphasizing risk factors.
  6. A 66-year-old female (64 kg) on warfarin for atrial fibrillation presents for an INR check. She started trimethoprim/sulfamethoxazole 160/800 mg by mouth twice daily 4 days ago for a urinary tract infection. Current medications: warfarin 5 mg by mouth daily, amiodarone 200 mg by mouth daily, levothyroxine 75 mcg by mouth daily. Allergies: none known. Medical history: atrial fibrillation, hypothyroidism. Labs today: INR 6.2 (goal 2–3), hemoglobin 10.8 g/dL (slightly low), aspartate aminotransferase 24 units/L (normal), alanine aminotransferase 20 units/L (normal). She reports new gum bleeding when brushing teeth. Which action should the pharmacist take to address this adverse event?
    Answer: Advise holding warfarin and contacting the prescriber urgently to manage supratherapeutic INR and switch antibiotics; counsel on bleeding precautions This question tests management of warfarin drug interactions causing supratherapeutic anticoagulation. The patient has a significantly elevated INR (6.2) with bleeding symptoms after starting trimethoprim/sulfamethoxazole, which inhibits CYP2C9 and reduces gut vitamin K production, potentiating warfarin's effect. Option A is correct because warfarin must be held immediately, the prescriber contacted urgently for INR management and antibiotic change, and bleeding precautions counseling provided. Option B is dangerous as it would worsen the already elevated INR. Option C is incorrect because this is a pharmacokinetic interaction, not an immune reaction requiring VAERS reporting. Option D dangerously ignores a critical INR elevation with active bleeding. The clinical pearl is that trimethoprim/sulfamethoxazole significantly increases warfarin effect through dual mechanisms; when antibiotics are needed in warfarin patients, INR should be checked within 3-5 days and alternative antibiotics considered for high-risk patients.
  7. A 46-year-old man (88 kg) started allopurinol 300 mg by mouth daily 12 days ago for gout prophylaxis. He now reports fever, facial swelling, and a widespread painful rash; he also notes dark urine and fatigue. Current medications: allopurinol 300 mg daily (new), colchicine 0.6 mg daily, hydrochlorothiazide 25 mg daily. Medical history: gout, hypertension. Allergies: none. Labs today: AST 210 U/L (high), ALT 240 U/L (high), SCr 2.0 mg/dL (baseline 1.0). Which action should the pharmacist take to address this adverse event?
    Answer: Advise immediate emergency evaluation for suspected severe cutaneous adverse reaction and instruct the patient to stop allopurinol; ensure the reaction is documented and reported This question tests the recognition and management of allopurinol hypersensitivity syndrome (AHS) as a severe adverse drug event. The key patient-specific factor is the onset of fever, facial swelling, widespread painful rash, dark urine, and elevated liver enzymes 12 days after starting allopurinol, with rising SCr. Advising immediate emergency evaluation for suspected severe cutaneous adverse reaction and stopping allopurinol while documenting and reporting is the best choice because AHS can progress to life-threatening organ involvement, requiring prompt discontinuation. Continuing allopurinol with topical hydrocortisone is incorrect as it does not address systemic involvement, while switching to febuxostat without prescriber input risks similar reactions in susceptible patients. Reporting to VAERS is inappropriate for non-vaccine events. A clinical pearl is to screen for HLA-B*5801 in high-risk populations before allopurinol initiation to prevent AHS. For reporting, use MedWatch for serious reactions, including details on genetics, labs, and dechallenge outcomes.
  8. A 31-year-old woman (64 kg) started clindamycin 300 mg by mouth four times daily 8 days ago for cellulitis. She now reports severe watery diarrhea (8 stools/day) and abdominal cramping. Current medications: clindamycin (day 8), probiotic supplement. Medical history: none. Allergies: none. Vitals: temperature 100.8°F. Labs: WBC 14,500/mm3 (high), SCr 1.2 mg/dL. Which action should the pharmacist take to address this adverse event?
    Answer: Advise prompt medical evaluation for possible Clostridioides difficile infection and recommend stopping clindamycin only if directed by the prescriber; avoid antidiarrheals until evaluated This question tests the recognition and management of antibiotic-associated diarrhea, specifically Clostridioides difficile infection (CDI) from clindamycin. The key patient-specific factor is the severe watery diarrhea, cramping, fever, and elevated WBC on day 8 of clindamycin therapy. Advising prompt evaluation for possible CDI, recommending to stop clindamycin only if directed, and avoiding antidiarrheals until evaluated is the best choice because clindamycin is high-risk for CDI, and antidiarrheals can worsen toxin retention. Recommending loperamide is incorrect as it delays diagnosis, while magnesium citrate is inappropriate for infectious diarrhea. Reporting to VAERS is suboptimal for antibiotic events. A transferable pearl is to suspect CDI with >3 loose stools/day post-antibiotic, testing with toxin assays. In adverse event management, prioritize diagnostic workup before symptomatic treatment and report confirmed CDI to infection control systems.
  9. A 34-year-old male (86 kg) calls the pharmacy 30 minutes after taking his first dose of amoxicillin/clavulanate 875/125 mg by mouth twice daily for sinusitis. He reports new generalized hives, lip swelling, and tightness in his throat. Current medications: none. Allergies: seasonal allergies only. Medical history: none. No labs available. What is the most important step in reporting this adverse drug reaction?
    Answer: Instruct the patient to call 911 immediately for possible anaphylaxis, then document the reaction and notify the prescriber; submit a MedWatch report once the patient is stabilized This question tests recognition and management of anaphylaxis as a severe adverse drug reaction. The patient exhibits classic signs of anaphylaxis (generalized hives, lip swelling, throat tightness) within 30 minutes of first amoxicillin/clavulanate dose, indicating IgE-mediated hypersensitivity. Option A is correct because anaphylaxis is a medical emergency requiring immediate 911 activation, followed by proper documentation and MedWatch reporting once the patient is stabilized. Option B is dangerous as it delays emergency treatment to complete paperwork first. Option C is incorrect because VAERS is specifically for vaccine adverse events, not antibiotics. Option D fails to capture critical details needed for adverse event reporting and patient safety. The clinical pearl is that anaphylaxis requires immediate emergency response first, then comprehensive documentation including timing, symptoms, and interventions, followed by FDA MedWatch reporting for serious adverse events. Pharmacists should document beta-lactam allergies prominently in all systems to prevent future exposures.
  10. A 41-year-old woman (68 kg) received her first dose of an mRNA COVID-19 vaccine yesterday and reports facial hives and wheezing that began 20 minutes after vaccination and required treatment at an urgent care clinic. Current medications: sertraline 50 mg daily. Medical history: seasonal allergies. Allergies: shellfish (hives). No labs available. What is the most important step in reporting this adverse drug reaction?
    Answer: Report the event to VAERS with vaccine product, lot number if available, timing, symptoms, and outcome This question tests the appropriate reporting pathway for vaccine-related adverse events. The key patient-specific factor is the onset of facial hives and wheezing 20 minutes after an mRNA COVID-19 vaccine dose, requiring urgent care treatment in a patient with allergy history. Reporting to VAERS with vaccine details, lot number, timing, symptoms, and outcome is the most important step because VAERS is the national system for monitoring vaccine safety, and anaphylaxis is a serious event requiring submission. Reporting only to MedWatch is incorrect as VAERS is specific for vaccines, while documenting only in the pharmacy profile omits mandatory reporting. Waiting for a second dose is suboptimal as it risks recurrence and delays surveillance. A clinical pearl is to observe patients with allergy history for 30 minutes post-vaccination. For reporting, include all available details in VAERS submissions to aid causality assessment and public health responses.
  11. A 63-year-old male (88 kg) with type 2 diabetes is started on empagliflozin 10 mg by mouth daily 2 weeks ago. He now reports painful urination, increased urinary frequency, and genital itching. Current medications: metformin 1000 mg by mouth twice daily, empagliflozin 10 mg by mouth daily, lisinopril 10 mg by mouth daily, atorvastatin 20 mg by mouth nightly. Allergies: none known. Medical history: type 2 diabetes, hypertension, hyperlipidemia. Labs today: serum creatinine 1.0 mg/dL (normal), glucose 168 mg/dL (high). Which action should the pharmacist take to address this adverse event?
    Answer: Assess for urinary tract infection or genital mycotic infection, refer for prompt evaluation and treatment, counsel on hygiene and hydration, and notify the prescriber if recurrent or severe This question tests recognition and management of SGLT2 inhibitor-associated genitourinary infections. The patient presents with classic symptoms of urinary tract infection or genital mycotic infection (dysuria, frequency, genital itching) after starting empagliflozin, which increases urinary glucose creating a favorable environment for infections. Option B is correct because assessment for UTI versus mycotic infection is needed, prompt evaluation and treatment are required, hygiene and hydration counseling help prevent recurrence, and the prescriber should be notified if infections are recurrent or severe. Option A incorrectly stops metformin instead of addressing the actual cause. Option C is incorrect as empagliflozin is not DEA-controlled. Option D dangerously suggests doubling the dose, which would worsen infection risk. The clinical pearl is that SGLT2 inhibitors significantly increase risk of genitourinary infections through glucosuria; patients should be counseled on hygiene measures, hydration, and early symptom recognition, with consideration for discontinuation if infections are recurrent.
  12. A 70-year-old woman (64 kg) received a new prescription for metoprolol succinate 100 mg by mouth daily but was mistakenly dispensed metoprolol tartrate 100 mg by mouth twice daily. After 3 days she reports lightheadedness and near-syncope. Current medications: metoprolol (dispensed as tartrate 100 mg twice daily), losartan 50 mg daily, levothyroxine 75 mcg daily. Medical history: hypertension. Allergies: none. Vitals: blood pressure 88/54 mmHg, heart rate 46 bpm. Which action should the pharmacist take to address this adverse event?
    Answer: Recommend urgent evaluation due to symptomatic bradycardia/hypotension, correct the dispensing error, notify the prescriber, and document per medication error policy This question tests the response to a medication dispensing error causing beta-blocker overdose symptoms as an adverse event. The key patient-specific factor is the erroneous dispensing of metoprolol tartrate twice daily instead of succinate once daily, leading to symptomatic bradycardia and hypotension after 3 days. Recommending urgent evaluation for bradycardia/hypotension, correcting the error, notifying the prescriber, and documenting per policy is the best choice because it addresses acute toxicity and prevents future errors through system improvements. Advising to continue with increased fluids is incorrect as it ignores symptomatic overdose, while changing to once daily without prescriber contact risks non-adherence to protocols. Submitting to VAERS is suboptimal for non-vaccine medication errors. A transferable pearl is to differentiate immediate- vs. extended-release formulations in counseling to avoid dosing errors. In adverse event management, apply the 'just culture' framework for errors, focusing on reporting to ISMP or FDA for learning and prevention.
  13. A 27-year-old woman (59 kg) begins taking minocycline 100 mg by mouth twice daily for acne. After 2 doses she reports dizziness and a spinning sensation, worse when standing. Current medications: minocycline (new), topical benzoyl peroxide. Medical history: none. Allergies: none. No labs available. Which action should the pharmacist take to address this adverse event?
    Answer: Assess severity and safety (falls), counsel that vestibular effects can occur with minocycline, and contact the prescriber if symptoms are intolerable to consider alternative therapy This question tests the management of vestibular adverse effects associated with minocycline therapy for acne. The key patient-specific factor is the dizziness and spinning sensation after 2 doses of minocycline, worsening on standing. Assessing severity and safety, counseling on vestibular effects, and contacting the prescriber if intolerable for alternatives is the best choice because minocycline can cause reversible vertigo, and evaluation ensures no falls while considering switches if needed. Recommending with alcohol is incorrect as it may worsen dizziness, while doubling the dose risks increased toxicity. Reporting to VAERS is inappropriate for non-vaccine events. A transferable pearl is to advise taking minocycline sitting or lying down and monitor for resolution within days. In adverse event management, use a symptom severity scale to decide on continuation versus discontinuation, and report persistent cases to MedWatch.
  14. A 59-year-old female (68 kg) with rheumatoid arthritis receives methotrexate 15 mg by mouth once weekly, but the prescription label was mistakenly printed as "take 15 mg by mouth daily." After 6 days of daily use, she presents with severe mouth ulcers, nausea, and fatigue. Current medications: methotrexate 15 mg (taken daily for 6 days due to label error), folic acid 1 mg by mouth daily, prednisone 5 mg by mouth daily, omeprazole 20 mg by mouth daily. Allergies: none known. Medical history: rheumatoid arthritis, gastroesophageal reflux disease. Labs today: white blood cell count 2.1 x103x10^3/mcL (low), platelets 88 x103x10^3/mcL (low), aspartate aminotransferase 96 units/L (high), alanine aminotransferase 110 units/L (high), serum creatinine 1.3 mg/dL (slightly high). What is the best recommendation for preventing future adverse events in this patient?
    Answer: Implement a weekly-dose methotrexate safety process (explicit "once weekly" directions, day-of-week specified, pharmacist counseling with teach-back, and independent double-check of labels for high-alert medications) This question tests medication error prevention strategies for high-alert medications. The patient experienced methotrexate toxicity (cytopenias, transaminitis, mucositis) due to a dispensing error resulting in daily instead of weekly administration, a well-documented fatal error pattern. Option A is correct because implementing systematic safety processes including explicit weekly dosing language, day-of-week specification, mandatory counseling with teach-back, and independent double-checks specifically addresses the root cause and prevents recurrence. Option B perpetuates the dangerous daily dosing. Option C inappropriately suggests patient self-adjustment of a high-alert medication. Option D violates patient safety principles by avoiding documentation needed for system improvement. The clinical pearl is that weekly methotrexate requires multiple safety barriers including computer alerts, explicit "once weekly" directions with specific day, mandatory pharmacist counseling, and independent verification; medication errors should always be documented and analyzed to improve systems and prevent future harm.
  15. A 67-year-old man (82 kg) presents to the pharmacy with new-onset dry cough that started 10 days after starting lisinopril 10 mg by mouth daily for hypertension. Current medications: lisinopril 10 mg daily (new), amlodipine 5 mg daily, atorvastatin 20 mg nightly. Allergies: none known. Labs from last week: serum creatinine (SCr) 1.0 mg/dL, potassium 4.6 mEq/L. He denies fever, sputum, wheezing, or shortness of breath. Which action should the pharmacist take to address this adverse event?
    Answer: Recommend the patient stop lisinopril and contact the prescriber to switch to an angiotensin II receptor blocker (ARB) This question tests the recognition and management of angiotensin-converting enzyme (ACE) inhibitor-induced cough as an adverse drug event. The key patient-specific factor is the new-onset dry cough starting 10 days after initiating lisinopril, with no signs of infection or other respiratory issues. Recommending discontinuation of lisinopril and switching to an angiotensin II receptor blocker (ARB) is the best choice because ACE inhibitor cough is mediated by bradykinin accumulation, which ARBs do not cause, providing effective hypertension control without this side effect. Continuing lisinopril with dextromethorphan is incorrect as the cough is not self-limited and may persist or worsen, while reporting to VAERS is inappropriate since it is for vaccine-related events, not medications. Increasing the lisinopril dose is suboptimal as it will not resolve the cough and may increase the risk of other adverse effects like hyperkalemia. A key clinical pearl is to always assess the temporal relationship between medication initiation and symptom onset when evaluating potential adverse drug events. For reporting, pharmacists should document such events in the patient profile and notify the prescriber to facilitate appropriate management and prevent recurrence.
  16. A 44-year-old man (85 kg) is taking metronidazole 500 mg by mouth three times daily for 10 days for a dental infection. He drank several beers last night and now reports flushing, nausea, vomiting, and palpitations. Current medications: metronidazole (day 4), lisinopril 10 mg daily. Medical history: hypertension. Allergies: none. No labs available. What is the best recommendation for preventing future adverse events in this patient?
    Answer: Counsel to avoid alcohol during metronidazole therapy and for at least 3 days after the last dose, and provide supportive care guidance This question tests the prevention of disulfiram-like reactions from metronidazole-alcohol interactions. The key patient-specific factor is the flushing, nausea, vomiting, and palpitations after consuming alcohol on day 4 of metronidazole therapy. Counseling to avoid alcohol during and for 3 days after metronidazole, with supportive care guidance, is the best recommendation because metronidazole inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde and symptoms. Switching to disulfiram is incorrect as it is for alcohol deterrence, not reaction treatment, while taking with alcohol worsens effects. Reporting to VAERS is inappropriate for this interaction. A clinical pearl is to extend alcohol avoidance to 72 hours post-metronidazole due to its half-life. For prevention, include interaction warnings in counseling and document patient education in adverse event frameworks.
  17. A 52-year-old female (78 kg) received a newly marketed extended-release metoprolol product and reports that after switching from her usual metoprolol succinate 50 mg by mouth daily to the new product at the same labeled dose, she developed dizziness and near-syncope within 24 hours. Current medications: new metoprolol extended-release 50 mg by mouth daily (started yesterday), hydrochlorothiazide 25 mg by mouth daily, sertraline 100 mg by mouth daily. Allergies: none known. Medical history: hypertension, depression. Vitals today: blood pressure 86/54 mmHg (low), pulse 42/min (low). Labs: serum creatinine 0.8 mg/dL (normal). What is the most important step in reporting this adverse drug reaction?
    Answer: Submit a report to FDA MedWatch including product name/manufacturer, lot number if available, dose, timing, and clinical outcome, and advise urgent medical evaluation for symptomatic bradycardia This question tests FDA MedWatch reporting requirements for newly marketed drug products causing serious adverse events. The patient experienced symptomatic bradycardia and hypotension after switching to a new extended-release metoprolol formulation, suggesting possible formulation issues or bioequivalence problems. Option A is correct because FDA MedWatch reports should include specific product identification (name, manufacturer, lot number), dosing details, timing, and clinical outcomes, while the patient needs urgent evaluation for symptomatic bradycardia. Option B is incorrect as pharmacists can and should report directly to FDA. Option C fails to report a potentially serious formulation issue affecting other patients. Option D is incorrect because VAERS is only for vaccines, not extended-release formulations. The clinical pearl is that pharmacists should report serious adverse events with newly marketed products to FDA MedWatch, including specific product details for investigation; bioequivalence issues with modified-release formulations can cause serious clinical consequences requiring vigilant monitoring.
  18. A 62-year-old man (86 kg) is picking up a new prescription for methotrexate 15 mg by mouth once weekly for rheumatoid arthritis, but the directions on the label mistakenly read "take 15 mg daily." Current medications: folic acid 1 mg daily, ibuprofen 200 mg as needed, methotrexate 15 mg (new). Medical history: rheumatoid arthritis. Allergies: none. Baseline labs: AST 22 U/L, ALT 25 U/L, SCr 1.0 mg/dL, CBC within normal limits. Which action should the pharmacist take to address this adverse event risk?
    Answer: Clarify and correct directions to once-weekly dosing before dispensing, provide explicit counseling on weekly administration, and document the near-miss per pharmacy policy This question tests the prevention of adverse events from methotrexate dosing errors in rheumatoid arthritis treatment. The key patient-specific factor is the labeling error directing daily instead of weekly methotrexate 15 mg, a high-alert medication. Clarifying and correcting to once-weekly dosing before dispensing, providing counseling, and documenting the near-miss is the best choice because weekly dosing prevents toxicity like pancytopenia, and error reporting improves safety. Dispensing as written risks severe harm from overdose, while advising daily for 7 days ignores standard regimens. Reporting only to VAERS is suboptimal for non-vaccine errors. A clinical pearl is to verify methotrexate directions and counsel on folic acid supplementation to mitigate risks. For adverse event prevention, use tall man lettering and double-checks for high-alert drugs, reporting near-misses to ISMP.
  19. A 65-year-old woman (66 kg) presents with new bruising and nosebleeds. She started apixaban 5 mg by mouth twice daily 2 weeks ago for a deep vein thrombosis. Current medications: apixaban 5 mg twice daily (new), sertraline 100 mg daily, naproxen 500 mg twice daily as needed (started 1 week ago). Medical history: DVT, depression. Allergies: none. Labs: hemoglobin 10.5 g/dL (low), SCr 0.9 mg/dL. Which action should the pharmacist take to address this adverse event?
    Answer: Assess bleeding severity and advise prompt medical evaluation; recommend avoiding NSAIDs like naproxen while on apixaban and contact the prescriber regarding bleeding risk This question tests the management of bleeding adverse events in patients on direct oral anticoagulants (DOACs) with interacting medications. The key patient-specific factor is the new bruising and nosebleeds with low hemoglobin 2 weeks after starting apixaban, concurrent with naproxen initiation. Assessing bleeding severity, advising prompt evaluation, recommending NSAID avoidance, and contacting the prescriber is the best choice because NSAIDs increase DOAC bleeding risk via platelet inhibition, requiring intervention. Adding aspirin worsens bleeding, while increasing apixaban is incorrect as it heightens risk without benefit. Reporting to VAERS is inappropriate for anticoagulants. A transferable pearl is to counsel on avoiding OTC NSAIDs with DOACs and monitor for bleeding signs like bruising. In adverse event management, use a framework assessing bleed site, severity, and reversibility, reporting major bleeds to MedWatch.
  20. A 39-year-old man (80 kg) started lamotrigine 25 mg by mouth daily 2 weeks ago for bipolar disorder with a planned titration schedule. He now reports a new rash on his trunk with low-grade fever. Current medications: lamotrigine 25 mg daily (new), lithium 300 mg twice daily. Medical history: bipolar disorder. Allergies: none. Labs: SCr 0.9 mg/dL; AST/ALT normal. Which action should the pharmacist take to address this adverse event?
    Answer: Advise stopping lamotrigine and seeking prompt medical evaluation due to concern for serious rash; notify the prescriber and document the reaction This question tests the management of lamotrigine-associated rash, potentially indicating serious cutaneous reactions. The key patient-specific factor is the new trunk rash with fever 2 weeks after starting lamotrigine titration in a bipolar patient. Advising to stop lamotrigine and seek prompt evaluation due to serious rash concern while notifying the prescriber and documenting is the best choice because lamotrigine can cause Stevens-Johnson syndrome, especially with rapid titration, requiring immediate cessation. Applying topical antifungal is incorrect as it assumes infection without evidence, while switching to carbamazepine without input risks similar rash potential. Reporting only to the manufacturer omits patient safety and profile documentation. A clinical pearl is to titrate lamotrigine slowly (e.g., 25 mg/week) to minimize rash risk. For reporting, submit to MedWatch for serious rashes, including titration details and resolution post-dechallenge.

Start this quiz